IN SB0375

Opioid treatment programs must conduct periodic and random drug tests on patients for methadone, cocaine, opiates, amphetamines, barbiturates, tetrahydrocannabinol, benzodiazepines, and any other suspected or known drugs of abuse.

Programs must administer at least 16 drug tests per 12-month period during each patient's treatment, with all tests conducted in an observed manner to prevent sample tampering.

Patients testing positive for unauthorized controlled substances or illegal drugs must receive a clinical evaluation from the onsite physician within 10 days and cannot take opioid medications until passing a random test.

Patients with positive tests must report to the facility daily (except when closed) and take weekly random tests until passing a test under the program requirements.

The clinical evaluation must recommend remedial action, which may include discharge from the program or increased supervision requirements.

Effective date: July 1, 2017.